Monash IVF Group Limited (ASX: MVF) has declined an unsolicited, non-binding proposal from a consortium led by Genesis Capital and WHSP Holdings to acquire all its shares for AU$0.80 per share. The Board said the offer significantly undervalues the company, noting that the implied 7.7x FY25 EV/EBITDA multiple is well below comparable IVF sector transactions. The proposal required exclusive due diligence, board unanimity, and further internal approvals, while the consortium already holds 19.6% of Monash IVF’s shares. Directors raised concerns about the proposal’s conditionality, financing uncertainty, and timing. Chairman Richard Davis described the bid as opportunistic, stating it fails to reflect Monash IVF’s strategic value. Shareholders are advised not to take action, with the Board reaffirming its commitment to act only on offers that deliver compelling value. Monash IVF has engaged Macquarie Capital to provide financial advisory support, while Clayton Utz has been selected to act as its legal counsel.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Monash IVF Rejects Takeover Bid
Monash IVF Group Limited (ASX: MVF) has declined an unsolicited, non-binding proposal from a consortium led by Genesis Capital and WHSP Holdings to acquire all its shares for AU$0.80 per share. The Board said the offer significantly undervalues the company, noting that the implied 7.7x FY25 EV/EBITDA multiple is well below comparable IVF sector transactions. The proposal required exclusive due diligence, board unanimity, and further internal approvals, while the consortium already holds 19.6% of Monash IVF’s shares. Directors raised concerns about the proposal’s conditionality, financing uncertainty, and timing. Chairman Richard Davis described the bid as opportunistic, stating it fails to reflect Monash IVF’s strategic value. Shareholders are advised not to take action, with the Board reaffirming its commitment to act only on offers that deliver compelling value. Monash IVF has engaged Macquarie Capital to provide financial advisory support, while Clayton Utz has been selected to act as its legal counsel.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au